Skip to content

Embecta Corp. EMBC Contract Liabilities and Refund Liability

Contract Liabilities and Refund Liability at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerRefundLiability.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s contract liabilities and refund liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s contract liabilities and refund liability?
Embecta Corp. (EMBC) reported contract liabilities and refund liability of $126.2M in Q1 2026.
How has Embecta Corp.'s contract liabilities and refund liability changed year-over-year?
Embecta Corp.'s contract liabilities and refund liability decreased by 1.7% year-over-year, from $128.4M to $126.2M.
What is the long-term trend for Embecta Corp.'s contract liabilities and refund liability?
Over 4 years (2021 to 2025), Embecta Corp.'s contract liabilities and refund liability has grown at a 12.2% compound annual growth rate (CAGR), from $71.7M to $113.7M.